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Abstract
Background: Elbow dislocations can be classified as simple or complex. Simple dislocations are characterized by
the absence of fractures, while complex dislocations are associated with fractures. After reduction of a simple
dislocation, treatment options include immobilization in a static plaster for different periods of time or so-called
functional treatment. Functional treatment is characterized by early active motion within the limits of pain with or
without the use of a sling or hinged brace. Theoretically, functional treatment should prevent stiffness without
introducing increased joint instability. The primary aim of this randomized controlled trial is to compare early
functional treatment versus plaster immobilization following simple dislocations of the elbow.
Methods/Design: The design of the study will be a multicenter randomized controlled trial of 100 patients who have
sustained a simple elbow dislocation. After reduction of the dislocation, patients are randomized between a pressure
bandage for 5-7 days and early functional treatment or a plaster in 90 degrees flexion, neutral position for pro-
supination for a period of three weeks. In the functional group, treatment is started with early active motion within the
limits of pain. Function, pain, and radiographic recovery will be evaluated at regular intervals over the subsequent 12
months. The primary outcome measure is the Quick Disabilities of the Arm, Shoulder, and Hand score. The secondary
outcome measures are the Mayo Elbow Performance Index, Oxford elbow score, pain level at both sides, range of
motion of the elbow joint at both sides, rate of secondary interventions and complication rates in both groups
(secondary dislocation, instability, relaxation), health-related quality of life (Short-Form 36 and EuroQol-5D), radiographic
appearance of the elbow joint (degenerative changes and heterotopic ossifications), costs, and cost-effectiveness.
Discussion: The successful completion of this trial will provide evidence on the effectiveness of a functional
treatment for the management of simple elbow dislocations.
Trial Registration: The trial is registered at the Netherlands Trial Register (NTR2025).
Background
The elbow joint is the second most commonly dislo-
cated joint in adults. The annual incidence of elbow dis-
locations in children and adults is 6.1 per 100,000 [1].
Elbow dislocations are classified as simple or complex
[2]. Simple dislocations are dislocations without frac-
tures. Complex dislocations are associated with (avul-
sion) fractures of the distal humerus, radial head, ulna,
or coronoid process. Conn et al. observed 414 injuries
of the elbow, which included 58 elbow dislocations in
both children and adults [3]. In 51% of these patients,
the dislocations were of the simple type. Josefsson et al.
observed 24 simple elbow dislocations in 52 patients
(46%) who were 16 years old and older [4].
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Elbow dislocations can also be classified by the direc-
tion of their displacement, i.e., posterior or anterior.
Posterior dislocations can be subdivided into medial and
lateral dislocations. Anterior dislocations are very rare.
In the study by Conn et al., 96% of the dislocations
were of the posterior or lateral type [3]. Moreover,
Josefsson et al. observed no anterior dislocations in 52
elbow dislocations [4].
Different treatment modalities can be applied follow-
ing reduction, including plaster immobilization, surgical
treatment of ruptured collateral ligaments, functional
treatment, or combinations. There is little available lit-
erature about treatment of elbow dislocations. One ran-
domized controlled trial (RCT) was identified in which
suture repair of the collateral ligaments was compared
with conservative treatment with plaster [5]. No differ-
ences were found for loss of extension and flexion after
more than one year, although a trend was found for
enhanced flexion at five and ten weeks for the plaster
group. However, this study lacked power, with a sample
size of only 14 patients in each arm. When comparing
functional treatment versus plaster immobilization, only
one RCT was retrieved from the literature [6]. Extension
and flexion of the elbow did not differ between the
groups after one year. Nevertheless, a difference in
elbow extension was observed at three months, favoring
the patients treated functionally. Furthermore, when two
observational studies were pooled comparing functional
treatment with plaster immobilization, functional treat-
ment showed a statistically significant better result for
pain and range of motion (ROM) [7,8].
Three observational studies comparing different peri-
ods of plaster immobilization after reduction showed a
larger ROM after shorter immobilization, but this find-
ing was statistically significant in only one study [9-11].
Moreover, these studies may be confounded by the
severity of the injury, as worse cases were probably
immobilized longer.
An important question following reduction of simple
elbow dislocations is whether or not the elbow is stable.
Signs of instability are redislocation, a positive pivot shift
test, positive valgus and varus stress testing, and radio-
graphic incongruence. In the studies described above,
stability testing was either not performed, or the tests dif-
fered between the studies. In these eight studies, only one
recurrent dislocation after plaster treatment was men-
tioned [7] (i.e., one recurrence in 342 patients (0.3%)),
and signs of gross instability were not mentioned. There-
fore, we conclude that the majority of the patients
included in these studies had simple dislocations, which
remained stable after reduction. For this type of disloca-
tion, literature suggests that plaster immobilization for
more than two weeks following reduction may lead to
limited ROM [12,13]. Therefore some authors state that
early functional treatment should be the treatment of
choice. Functional treatment is defined as early active
movements within the limits of pain with or without the
use of a sling or a hinged brace [6-8].
A recent electronic survey of 90 trauma surgeons in
the Netherlands revealed that 60% of the patients with a
simple elbow dislocation were generally treated with
plaster immobilization for three weeks or longer [14].
The primary objective of this study is to compare the
Quick-DASH (Disabilities of the Arm, Shoulder, and
Hand) questionnaire scores after functional treatment ver-
sus plaster immobilization in adult patients who sustained
a simple elbow dislocation. Secondary aims are to examine
the effect of functional treatment versus plaster immobili-
zation on functional outcome (Mayo Elbow Performance
Index (MEPI) and Oxford elbow score), the level of pain
(Visual Analog Scale (VAS)), ROM, the rate of secondary
interventions and complications, health-related quality of
life (Short Form-36 (SF-36) and EuroQol-5D (EQ-5D)),
costs, and cost-effectiveness in these patients.
Methods/Design
Study design
The FuncSiE trial will follow a multicenter, randomized
controlled trial design. Twenty-five centers in the
Netherlands will participate. The study started August
26, 2009.
Recruitment and consent
Eligible patients presenting to the emergency depart-
ment (ED) with a simple elbow dislocation will be
informed about the trial at the ED after reduction of the
dislocated elbow. They will receive written information
and a consent form from the attending physician, the
clinical investigator or a research assistant. After provid-
ing informed consent, eligible patients will be rando-
mized within one week. Participants will be allocated to
one of two treatment arms using a web-based randomi-
zation program that will be available 24 hours a day.
Variable block randomization will be accomplished via a
trial website. Allocation will be at random.
It is not possible to blind surgeons and patients for
the allocated treatment. In order to reduce bias, an
independent researcher without knowledge of the pre-
scribed treatment will perform follow-up measurements.
In addition, radiographs will be blinded and evaluated in
duplicate, and analysis will be done in a blinded fashion.
Study population
All persons aged 18 years or older presenting with a
simple elbow dislocation at the Emergency Departments
of the participating clinics are eligible for inclusion.
Patients meeting the following inclusion criteria are
eligible for enrolment:
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1. Adult men or women aged 18 years and older (with
no upper age limit)
2. A simple dislocation of the elbow (i.e., without asso-
ciated fracture) that can be reduced by closed means.
Presence of a dislocation and absence of fracture(s) will
be confirmed by a plain X-ray
3. Provision of informed consent by patient
If any of the following criteria applies, patients will be
excluded:
1. Polytraumatized patients
2. Patients with complex, pathological, recurrent or
open dislocations
3. Additional traumatic injuries of the affected arm
4. Patients undergoing surgical repair of collateral liga-
ments of the dislocated elbow joint
5. Patients with an impaired elbow function (i.e., stiff
or painful elbow or neurological disorder of the upper
limb) prior to the injury
6. Retained hardware around the affected elbow
7. History of operations or fractures involving the
elbow
8. Patients with rheumatoid arthritis
9. Likely problems, in the judgment of the investiga-
tors, with maintaining follow-up (e.g., patients with no
fixed address)
10. Insufficient comprehension of the Dutch language
to understand a rehabilitation program and other treat-
ment information, which will be judged by the attending
physician
Exclusion of a patient because of enrolment in another
ongoing drug or surgical intervention trial will be left to
the discretion of the attending surgeon on a case-by-
case basis.
Intervention
Reduction can be performed under general, regional, or
local anesthesia or without anesthesia, depending upon
the preference of the surgeon. The method of choice
will be recorded, but not standardized.
Following reduction, the affected arm will be put in
either a pressure bandage (e.g., Tubigrip®) or a plaster of
Paris for three weeks. Both treatment groups will be
advised to use a sling; 5-7 days for the functional group,
and up to three weeks in the plaster group.
In the functional group, early active movements
within the limits of pain are allowed. Patients will be
free to select their own physical therapist. Physical
therapy is commenced after two days according to a
predefined protocol. Patients will be asked to hand
over to their physical therapist the following instruc-
tions. Exercises will be performed in a supine overhead
position with the shoulder flexed at 90°. When coming
into the overhead position, the shoulder is held in
adduction and neutral to external rotation. The arm is
not allowed to cross the midline. This position is
controlled by holding the wrist with the healthy hand.
In the supine position, with the shoulder in 90° of for-
ward flexion and the forearm maintained in pronation
(with the forearm resting on the forehead), gentle
active assisted supination and pronation is performed.
The second exercise is performed in the same position.
The shoulder is placed in 90° of forward flexion and
the elbow in 90° or more flexion. The forearm is held
in full pronation. Gentle active and active assisted
elbow flexion to full range and elbow extension are
performed as tolerated and are not to exceed 30°.
After three weeks, the sling will be removed, and the
supine exercises will be replaced by active and active
assisted elbow and forearm motions in the sitting or
standing positions.
The plaster group is immobilized for three weeks and
after removal of the plaster physical therapy is initiated
according to the same protocol as described above.
Outcome measures
The primary outcome measure is the Quick-DASH (Dis-
abilities of the Arm, Shoulder and Hand) score, which
reflects both function and pain [15]. The DASH Outcome
Measure is a validated 30-item, self-reported questionnaire
designed to help describe the disability experienced by
people with upper-limb disorders and also to monitor
changes in symptoms and function over time [15,16].
The Quick-DASH is a shortened version of the DASH
Outcome Measure. Instead of 30 items, the Quick-
DASH uses 11 items (scored 1-5) to measure physical
function and symptoms in people with any or multiple
musculoskeletal disorders of the upper limb. The right
and left elbow will be assessed separately. At least 10 of
the 11 items must be completed for a score to be calcu-
lated. The scores will be transformed to a 0-100 scale
for easy comparison. A higher score indicates greater
disability.
Like the DASH, the Quick-DASH contains 2 optional
modules to measure symptoms and function in athletes,
performing artists and other workers whose jobs require
a high degree of physical performance. These optional
models are scored separately; each contains four items,
scored 1-5. All items must be completed for a score to
be calculated.
The secondary outcome measures are:
• Functional outcome (Mayo Elbow Performance
Index and Oxford Elbow Score)
• Pain level at both sides (VAS)
• Range of Motion of the elbow joint at both sides
• Rate of secondary interventions
• Rate of complications (secondary dislocation,
instability, relaxation)
• Health-related quality of life: SF-36 and EQ-5D
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• Radiographic appearance of elbow joint (degenera-
tive changes and heterotopic ossifications)
• Cost
• Cost-effectiveness
The MEPI index is one of the most commonly used
physician-based elbow rating systems. This index con-
sists of five parts: pain (with a maximum score of 45
points), ulnohumeral motion (20 points), stability (ten
points), the ability to perform five functional tasks (5 ×
5 points) and the patient response. If the total score is
between 90 and 100 points, it is considered excellent;
between 75 and 89 points, good; between 60 and 74
points, fair; and less than 60 points, poor [17].
The Oxford elbow score is a 12-item questionnaire. It
is comprised of three one-dimensional domains: elbow
function, pain and social-psychological, with each
domain comprising 4 items with good measurement
properties [18]. This is a validated questionnaire in the
UK and was translated to Dutch by the proper transla-
tion procedure, which uses the technique of translation
and back-translation [19]. Permission for translation and
the use of the OES for this study was obtained from
Oxford and Isis Outcomes, part of Isis Innovation Lim-
ited (website: http://www.isis-innovation.com/)
Pain level will be determined using a 10-point Visual
Analog Scale (VAS), in which zero implies no pain and
ten implies the worst possible pain.
ROM will be measured on both sides using a
goniometer.
Secondary interventions within one year of initial
treatment to relieve pain or improve function will be
recorded. This includes secondary revision of collateral
ligaments and external fixator placement.
Complications within one year of initial treatment will
be recorded. These include redislocation, pressure
necrosis (plaster group only), post-traumatic dystrophy,
and neurologic deficit.
The Short-Form 36 (SF-36) is a validated multi-
purpose, short-form health survey with 36 questions
that represent eight health domains that are combined
into a physical and a mental component scale [20].
The Physical Component Scale (PCS) combines the
health domains of physical functioning (PF; ten items),
role limitations due to physical health (RP; four items),
bodily pain (BP; two items), and general health percep-
tions (GH; five items). The Mental Component Scale
(MCS) combines the health domains of vitality, energy,
or fatigue (VT; four items), social functioning (SF; two
items), role limitations due to emotional problems (RE;
three items), and general mental health (MH; five
items). Scores ranging from zero to 100 points are
derived for each domain, with lower scores indicating
poorer function. These scores will be converted to a
norm-based score and compared with the norms for
the general population of the United States (1998), in
which each scale was scored to have the same average
(50 points) and the same standard deviation (ten
points).
The EuroQol-5D is a validated questionnaire for
health-related quality of life [21,22].
Radiographic appearance (anteroposterior and lateral
X-ray at one year): heterotopic ossification will be classi-
fied according the classification scheme of Broberg and
Morrey as a bone exostosis or as a soft tissue ossifica-
tion of a ligament, capsule or muscle (“myositis ossifi-
cans”) [23]; degenerative changes will be classified as
grade zero (no change), grade 1 (slight narrowing of the
joint space with small osteophytes), grade 2 (moderate
narrowing of the joint space, osteophytes and subchon-
dral sclerosis), and grade 3 (severe narrowing of the
joint space, large osteophytes, subchondral sclerosis and
cystic deformation).
The incremental cost-effectiveness ratio of functional
versus plaster treatment will be expressed in a cost-uti-
lity ratio, i.e., in terms of cost per QALY. The economic
evaluation will be performed from a societal perspective,
and will include both health care costs and costs of pro-
duction losses. Health care costs will include costs of
general practice care, medical specialist care, physical
therapy, hospitalization, medication, and other costs
directly associated with diagnosis, treatment and rehabi-
litation. Patients will be asked to administer a custom-
made questionnaire to register their health care needs
and production loss.
In addition to the outcome variables mentioned above,
the following data will be collected:
a) Intrinsic variables (baseline data): age, gender,
American Society of Anesthesiologists’ ASA classifica-
tion, tobacco consumption, alcohol consumption,
comorbidity, social status/household composition, domi-
nant side, and medication use.
b) Injury related variables: affected side, mechanism of
injury, and assessment of varus, valgus and posterolat-
eral rotatory instability.
c) Intervention-related variables: reduction delay (i.e.,
time between dislocation and reduction), time between
injury and start of physical therapy, days of sling use,
and number of physical therapy sessions
Study procedures [Table 1]
Clinical assessments will occur at the time of admission
(baseline), one week (3-10-day window), three weeks
(11-28-day window), six weeks (4-8-week window),
three months (11-15-week window), six months (5-7-
month window), and 12 months (12-14-month window)
after start of treatment.
At each FU visit, the research coordinator or research
assistant will ascertain patient status (i.e., secondary
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interventions, adverse events/complications, deaths) and
will verify information within medical records.
At each FU visit, the patients will be asked to indicate
the pain level on a VAS.
At each visit from six weeks onwards, the ROM of the
elbow will be measured using a goniometer by a doctor
blinded for the treatment of the dislocation. This will be
used to calculate the MEPI index. In addition, patients
will be asked to complete the questionnaires relating to
disability (Quick-DASH score including optional mod-
ules, Oxford Elbow Score), health-related quality of life
(SF-36, EQ-5D), and healthcare consumption.
Plain X-rays of the elbow will be made at the time of
presentation in the hospital (baseline), post-reduction,
and at the follow-up visit after one week and one year.
The X-ray at 12 months will be taken in order to deter-
mine the amount and location of heterotopic ossifica-
tion and the grade of degenerative joint changes. This is
common practice in this type of patient. At the last
visit, the surgeon will document any surgery that may
be planned for the patient.
Sample size calculation
Calculation of the required sample size is based upon
the assumption that the mean Quick-DASH will be 12.5
in plaster treated patients and five in the functional
group, assuming a standard deviation of 15 for the plas-
ter group and 7.5 for the functional group [7]. A 2-sided
test with an a level of 0.05 and a b level of 0.2 requires
41 patients in each group. Anticipating a dropout rate
of 20% loss to follow-up a sample size of 50 patients in
each arm is required.
Statistical analysis
Data will be analyzed using the PASW Statistics version
18.0.1 or higher (SPSS, Chicago, Illinois, USA). Normal-
ity of continuous data will be tested with the Shapiro-
Wilk and Kolmogorov-Smirnov test and by inspecting
the frequency distributions (histograms). The homoge-
neity of variances will be tested using the Levene’s test.
The analysis will be performed on an intention to
treat basis. Patients with protocol violations will be fol-
lowed up, and data will be recorded. Data will be ana-
lyzed with and without inclusion of patients with
protocol violation.
Descriptive analysis will be performed to report base-
line characteristics (intrinsic variables and injury-related
variables) in both treatment groups. For continuous
data (e.g., age, Quick-DASH score at baseline) mean ±
SD (parametric data) or medians and percentiles (non-
parametric data) will be calculated. For categorical data
(e.g., gender, ASA grade, alcohol and tobacco
Table 1 Schedule of events
Screening Enrollment Baseline 1 week 3 weeks 6 weeks 3 months 6
months
12 months
(3-10 d) (11-28 d) (4-8 we) (11-15 we) (5-7 mo) (12-14 mo)
Screening X
X-ray X X (<24 h post-
reduction)
X X
Informed Consent X
Randomization X
Baseline data X
Clinical follow-up X X X X X X
Revisision surgery X X X X X X
Complications X X X X X X
Pain (VAS) X X X X X X
Quick-DASH X X X X
MEPI X X X X
Oxford Elbow Score X X X X
SF-36 X X X X
EQ-5D X X X X
Health care
consumption
X X X X
ROM X X X X
Early withdrawal * * * * * *
*, only if applicable.
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consumption, dominant and affected side) frequencies
will be calculated.
The mean difference between the mean Quick-DASH
scores of the functional group and the plaster group
will be tested. Univariate analysis will be performed to
test the difference in the primary and secondary out-
come measures between the functional and the plaster
groups. Continuous data will be tested using a Student’s
T-test (parametric data) or a Mann Whitney U-test
(non-parametric data). Chi-square analysis will be used
for statistical testing of categorical data. A p-value <0.05
will be taken as the threshold of statistical significance.
A multivariable linear regression analysis will be
performed to model the relationship between different
covariates and the Quick-DASH score. Intrinsic and
injury-related variables that display a p-value <0.5 in the
univariate analyses will be added as a covariate.
Ethical considerations
The study will be conducted according to the principles
of the Declaration of Helsinki (59th World Medical
Association General Assembly, Seoul, October 2008)
and in accordance with the Medical Research Involving
Human Subjects Act (WMO).
The Medical Ethics Committee Erasmus MC (Rotterdam,
The Netherlands) acts as central ethics committee
for this trial (reference number MEC-2009-239;
NL28124.078.09). Approval has been obtained from the
local Medical Ethics Committees in all participating
centers. An information letter notifying the patients’
participation will be sent to their general practitioners,
unless a patient does not agree with this.
The Medical Ethics Committee Erasmus MC has given
dispensation from the statutory obligation to provide
insurance for subjects participating in medical research
(article 7, subsection 6 of the WMO and Medical
Research (Human Subjects) Compulsory Insurance
Decree of 23 June 2003). The reason for this dispensa-
tion is that participation in this study is without risks.
Discussion
The FuncSiE trial will compare management of simple
elbow dislocations by early functional treatment with
treatment by plaster immobilization. Early functional
treatment may lead to a better ROM and prevent elbow
stiffness. To date no RCT for the management of simple
elbow dislocation has been performed with a sample
size of 100 patients. Inclusion of patients has been
started August 26, 2009 and the expectation is to
include 8 patients per month. With a follow-up of one
year the presentation of data will be expected in the
beginning of 2012.
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